Skip to main content

Table 5 Predictors of cancer-specific mortality in patients with castration-resistant prostate cancer

From: Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis

  Univariate Multivariate
  HR (95% CI) P HR (95% CI) p
Age 1.038 (1.016–1.061) 0.001 1.020 (0.998–1.042) 0.069
Body mass index 0.968 (0.901–1.041) 0.382    
PSAa 1.001 (1.000-1.001) < 0.001 1.001 (1.000–1.001) 0.018
Hemoglobina 1.001 (0.999-1.002) 0.306    
Albumina 0.408 (0.301-0.553) < 0.001    
Alkaline phosphatasea 1.001 (1.000–1.001) < 0.001 1.001 (1.001–1.002) < 0.001
T stage (≥T3 vs. ≤T2) 0.865 (0.524–1.430) 0.271    
N stage (1 vs. 0) 1.251 (0.922–1.697) 0.152    
M stage (1 vs. 0) 1.528 (0.983–2.376) 0.062    
Gleason score (≥8 vs. ≤7) 1.957 (1.441–2.658) < 0.001 2.004 (1.452–2.767) < 0.001
CCI ≥4 1.197 (0.811–1.765) 0.365    
ECOG ≥2 1.802 (1.216–2.670) 0.003 1.304 (1.164–2.158) 0.035
Docetaxel cycles 0.926 (0.900–0.953) 0.026 0.943 (0.915–0.972) 0.011
Primary treatment
 Prostatectomy 1 (reference)     
 Radiation therapy 0.778 (0.580–1.141) 0.584    
ARAT agent sequencing
 Pre-chemotherapy 1 (reference)     
 Post-chemotherapy 0.865 (0.524–1.430) 0.572    
Radium-223 administration 0.803 (0.255–2.527) 0.707    
Clinical trial participation 0.593 (0.417–0.843) 0.004 0.585 (0.429–0.797) 0.038
  1. aLaboratory values at diagnosis of castration-resistant prostate cancer
  2. Abbreviations: ARAT androgen receptor axis-targeted, CI confidence interval, CCI Charlson Comorbidity Index, ECOG PS Eastern Cooperative Oncology Group performance status, HR hazard ratio, PSA prostate-specific antigen